1. Home
  2. OI vs ANIP Comparison

OI vs ANIP Comparison

Compare OI & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo O-I Glass Inc.

OI

O-I Glass Inc.

HOLD

Current Price

$15.43

Market Cap

2.0B

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$80.82

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OI
ANIP
Founded
1903
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OI
ANIP
Price
$15.43
$80.82
Analyst Decision
Buy
Strong Buy
Analyst Count
7
7
Target Price
$16.29
$102.14
AVG Volume (30 Days)
2.3M
421.3K
Earning Date
11-04-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.67
Revenue
$6,455,000,000.00
$826,880,000.00
Revenue This Year
$1.41
$43.41
Revenue Next Year
$1.99
$9.66
P/E Ratio
N/A
$49.08
Revenue Growth
N/A
48.87
52 Week Low
$9.23
$52.50
52 Week High
$16.04
$99.50

Technical Indicators

Market Signals
Indicator
OI
ANIP
Relative Strength Index (RSI) 73.59 37.39
Support Level $13.01 $80.30
Resistance Level $14.60 $83.60
Average True Range (ATR) 0.49 2.29
MACD 0.17 0.23
Stochastic Oscillator 99.46 39.61

Price Performance

Historical Comparison
OI
ANIP

About OI O-I Glass Inc.

O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: